Uveitis Clinical Trials 2024

Uveitis Clinical Trials 2024

Uveitis research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in uveitis clinical trials today.

Popular filter options for uveitis trials

Intermediate Uveitis Clinical Trials

View 6 Intermediate Uveitis medical studies.

Uveitis Clinical Trials With No Placebo

View 15 uveitis medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to uveitis

What are the top hospitals conducting uveitis research?

When it comes to cutting-edge clinical trials in the field of uveitis, several hospitals across the United States are making significant strides. Texas Retina Associates, located in Plano, has emerged as a leader with three active uveitis trials and a total of three completed trials dedicated to this condition. The hospital first delved into uveitis research in 2022, marking an exciting milestone in their efforts to advance treatment options for patients. Meanwhile, all the way on the west coast, the University of California, San Francisco has been actively involved in studying uveitis since 2015. With two ongoing trials and four completed studies under their belt, they continue to push boundaries at one of the nation's top medical institutions.

Furthermore highlighting innovation is Seattle Children's Hospital known for its groundbreaking pediatric care; here they conducted pioneering investigation regarding Uveitis cases way back until 2020 and currently possess two active endeavors towards same goal.Children's Hospital of Philadelphia also made notable contributions by initiating examinations tailored specifically towards understanding Uveitistwo years ago sharing similar numbers with Seattle children’s hospital.Currently both Tennessee Retina located at Nashville alongside Children’s National Hospital basedin Washington D.C.have initiated investigations revolving aroundnovel therapeutic approaches against Uvritis individually holding two respective investigations each; while Tennessee retina tookofficiating steps only recent yearin2019Children’s national hopitalhas held prior investigatory tests throughout past decade till now.

These remarkable hospitals demonstrate not only their commitment to advancing our knowledge and treatment options for uveitis but also their dedication to patient care. Their tireless efforts contribute significantly to improving outcomes for individuals affected by this complex eye condition nationwide

Which are the best cities for uveitis clinical trials?

When it comes to uveitis clinical trials, several cities in the United States are at the forefront of research and innovation. Nashville, Tennessee leads with 7 active trials investigating treatments like Adalimumab (ADA), Brepocitinib, and Abatacept Injection. Plano and Bellaire in Texas join the ranks with 6 ongoing studies each, focusing on Brepocitinib, Yutiq 0.18 MG Drug Implant, Izokibep, and other potential therapeutic options. San Francisco in California also contributes significantly with 6 active trials exploring Izokibep, Metagenomic Deep Sequencing (MDS), Abatacept Injection among others. Salt Lake City in Utah follows closely behind with 5 active trials examining treatments including Brepocitinib and Adalimumab (ADA). These cities offer individuals affected by uveitis access to cutting-edge clinical trials that may shape future treatment approaches for this condition.

Which are the top treatments for uveitis being explored in clinical trials?

Exciting developments are underway in the exploration of new treatments for uveitis, a condition that affects the eye. Leading the charge is brepocitinib, yutiq 0.18 MG Drug Implant, izokibep, and metagenomic deep sequencing (MDS). Each treatment shows promise with one active trial dedicated to uveitis and first listed in 2022. These innovative approaches offer hope for improved management of this challenging condition and may pave the way towards better outcomes for patients.

What are the most recent clinical trials for uveitis?

Recent clinical trials have provided promising insights into the treatment of uveitis, a condition that affects the eye's middle layer. One such study investigated ESK-001 Dose Level 1, which showed potential in managing uveitis symptoms during Phase 2 trials. Another trial assessed the effectiveness of high-dose UME - 6 drops OCS-01 as a possible treatment option for uveitis patients. Brepocitinib, an experimental drug currently in Phase 2 trials, also holds promise as a potential therapy for this condition. Additionally, Yutiq 0.18 MG Drug Implant has shown positive results in its Phase 3 trial and may offer new possibilities for long-term uveitis management. Finally, Izokibep is being evaluated in Phase 2 studies to determine its efficacy against uveitis-related inflammation and complications. These ongoing investigations bring hope to individuals suffering from this challenging ocular disease.

What uveitis clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of uveitis research. In January 2022, Affibody concluded its trial for Izokibep, a potential treatment option. Equally noteworthy is the completion of the TRS01 trial by Tarsier Pharma in September 2021. Although not as recent, it's worth mentioning that Eye Pharma completed their Norflo Oro trial back in December 2018. These advancements demonstrate ongoing efforts to advance our understanding and develop effective therapies for uveitis patients.